The hemoglobinopathies market size was exhibited at USD 10.52 billion in 2024 and is projected to hit around USD 34.76 billion by 2034, growing at a CAGR of 12.7% during the forecast period 2025 to 2034.
The U.S. hemoglobinopathies market size is evaluated at USD 3.0 billion in 2024 and is projected to be worth around USD 9.91 billion by 2034, growing at a CAGR of 14.47% from 2025 to 2034.
North America held the largest revenue share of 38.0% of the market in 2024, owing to increasing awareness of hemoglobinopathies among people and improving healthcare facilities. Various organizations spread awareness by conducting different programs. For instance, SCDAA is a national organization in the United States that promotes awareness, advocacy, and support for individuals and families affected by sickle cell disease. They provide resources and educational materials and host events to increase understanding and improve the lives of those with the condition. Various initiatives undertaken by research organizations and government bodies to promote research to develop novel therapies for treating hemoglobinopathies are likely to contribute to the market growth in the region.
Asia Pacific is anticipated to exhibit the fastest growth rate over the forecast period. The presence of many patients with sickle cell disease and thalassemia is expected to propel market growth in the coming years. Favorable government initiatives to improve the standard of care provided to patients affected with hemoglobinopathies contribute to the region's market growth. For instance, in May 2023, the Union Minister of State for Health and Family Welfare launched the third phase of the Thalassemia Bal Sewa Yojana of the Health Ministry. The government also launched Thalassemia Bal Sewa Yojana Portal.
| Report Coverage | Details |
| Market Size in 2025 | USD 11.85 Billion |
| Market Size by 2034 | USD 34.76 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 12.7% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Type, Diagnosis, Therapy, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Sangamo Therapeutics; bluebird bio, Inc.; Global Blood Therapeutics, Inc.; Pfizer, Inc.; Emmaus Life Sciences, Inc.; Prolong Pharmaceuticals, LLC; Celgene Corporation; Bioverativ Inc.; Gamida Cell; Novartis AG |
The sickle cell disease segment held the largest share of 58.61% of the market in 2024 and is expected to grow at the fastest CAGR during the forecast period. This is attributed to biopharmaceutical companies' growing initiatives, and nonprofit organizations focused on improving access to SCD treatment. Furthermore, SCD affects around 300,000 newborns annually. An estimated 10% to 40% of the individuals in many African countries are carriers of the sickle cell gene, which has resulted in a prevalence of around 2% in these countries. The increasing global disease burden is expected to fuel market growth over the forecast period.
In addition, awareness programs for disease diagnosis play an important role in the market's growth. For instance, in the United States, various sickle cell disease awareness programs focus on promoting early diagnosis and providing support. Organizations like the Sickle Cell Disease Association of America (SCDAA) and local chapters organize educational events, community workshops, and health fairs. They collaborate with healthcare professionals to offer free or subsidized screenings, genetic counseling, and educational resources to increase awareness and improve early detection of sickle cell disease among high-risk populations.
Furthermore, several scientific facilities are conducting trials to develop new cures and methods for these diseases. For instance, in May 2023, the researchers and scientists at the University of Colorado successfully treated a patient with SCD, who is now cured due to a clinical trial for gene therapy.
The sickle cell disease diagnosis segment dominated the market and accounted for a 50.46% share in 2024 and is expected to grow at fastest CAGR during the forecast period. The sickle cell disease diagnosis market has witnessed prominent trends in recent years. One substantial trend is the development and adoption of innovative diagnostic technologies. Advances in genetic testing, including next-generation sequencing and molecular diagnostics, have enabled more accurate and efficient identification of sickle cell disease and its variants. Point-of-care testing (POCT) devices and rapid diagnostic kits have also emerged, allowing for quick and convenient screening in various healthcare settings. For instance, in May 2023, Molbio Diagnostics collaborated with ShanMukha Innovations to design, develop, and commercialize reasonably priced point-of-care diagnostic devices for diagnosing hemoglobinopathy-related diseases.
The market for hemoglobinopathies has also seen an increased focus on newborn screening programs, ensuring early detection and timely interventions. Furthermore, there is a growing emphasis on expanding access to diagnostic services in underserved regions, improving overall patient care and outcomes.
The sickle cell disease segment held the largest revenue share of 63.0% of the hemoglobinopathies market in 2024 and is expected to grow at fastest CAGR during the forecast period. Development and approval of novel therapies, including gene therapies and targeted therapies, aimed at modifying the underlying genetic abnormalities or managing disease symptoms is one of the major factor driving the market growth. In addition, stem cell transplantation, particularly from matched unrelated donors, is also gaining traction as a curative treatment option. Additionally, there is a growing focus on supportive care interventions such as pain management, infection prevention, and hydroxyurea therapy. Furthermore, there is an increasing emphasis on personalized medicine approaches and patient-centric care models to optimize treatment outcomes for individuals with sickle cell disease.
Blood transfusion is considered to be the first line of treatment for hemoglobin disorders. The frequency of blood transfusion is higher in thalassemia cases as compared to other hemoglobinopathies. The transfusion is done every 3 to 4 weeks to help maintain the normal level of blood components. However, blood transfusion at frequent intervals increases the risk of acquiring infectious diseases and high blood iron levels. In 2020, the blood supply was interrupted because of a complete lockdown due to COVID-19 in many countries. This supply has now gotten back up and is expected to reach its potential status over the forecast period.
Bone marrow transplant (BMT) therapy is expected to expand at a significant growth rate over the forecast period. BMT is often used when blood transfusion and other therapies fail. BMT is reported to be effective when performed in the early stages of disease progression. It helps to provide healthy bone marrow to patients who are unable to produce a sufficient number of normal cells. BMT infuses healthy stem cells in the patient’s body to replace the diseased or damaged bone marrow and is increasingly being used to treat severe cases of sickle cell disease and thalassemia.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the hemoglobinopathies market
By Type
By Diagnosis
By Therapy
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers